BiotechTube

Inotersen + Eplontersen

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Conditions

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Trial Timeline

Dec 11, 2019 → Jul 12, 2023

NCT ID
NCT04136184

About Inotersen + Eplontersen

Inotersen + Eplontersen is a phase 3 stage product being developed by Ionis Pharmaceuticals for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT04136184. Target conditions include Hereditary Transthyretin-Mediated Amyloid Polyneuropathy.

What happened to similar drugs?

3 of 20 similar drugs in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy were approved

Approved (3) Terminated (0) Active (17)
✅Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injectionCSLApproved
✅GaradacimabCSLApproved
✅IdebenoneSanthera PharmaceuticalsApproved
🔄KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
🔄KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04136184Phase 3Completed

Competing Products

20 competing products in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

See all competitors
ProductCompanyStageHype Score
KVD900KalVista PharmaceuticalsPhase 2
29
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 1
23
KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
38
SebetralstatKalVista PharmaceuticalsPre-clinical
20
KVD900 + Placebo to KVD900KalVista PharmaceuticalsPhase 1
23
SebetralstatKalVista PharmaceuticalsPre-clinical
24
Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
34
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tabletKalVista PharmaceuticalsPhase 1
23
KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
34
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 2
21
KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3
38
Deferasirox FCTNovartisPhase 2
27
Canakinumab + PlaceboNovartisPhase 3
40
IlarisNovartisPre-clinical
33
Standard of Care for Haemophilia ARochePre-clinical
26
EmicizumabRochePhase 3
40
TafamidisPfizerPre-clinical
26
tafamidisPfizerPre-clinical
26
NitisinoneSwedish Orphan BiovitrumPre-clinical
26
NitisinoneSwedish Orphan BiovitrumPhase 1
29